Alligator Bioscience AB (publ) (ATORX.ST)
SEK 6.3
(-3.37%)
SEK 6.3
(-3.37%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 307.09 Million SEK | 31.75% |
| 2022 | 227.99 Million SEK | 47.76% |
| 2021 | 154.3 Million SEK | 3.99% |
| 2020 | 148.38 Million SEK | -31.78% |
| 2019 | 217.52 Million SEK | 21.43% |
| 2018 | 179.14 Million SEK | 49.4% |
| 2017 | 119.9 Million SEK | 29.17% |
| 2016 | 92.82 Million SEK | 4.55% |
| 2015 | 88.78 Million SEK | 15.08% |
| 2014 | 77.15 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 52.98 Million SEK | -17.97% |
| 2024 Q3 | 64.24 Million SEK | 19.78% |
| 2024 Q1 | 64.59 Million SEK | -19.87% |
| 2023 Q3 | 72.36 Million SEK | -10.72% |
| 2023 Q2 | 81.04 Million SEK | 11.97% |
| 2023 FY | 300.39 Million SEK | 31.75% |
| 2023 Q1 | 72.38 Million SEK | 0.49% |
| 2023 Q4 | 80.62 Million SEK | 11.41% |
| 2022 Q1 | 48.57 Million SEK | 16.88% |
| 2022 FY | 227.99 Million SEK | 47.76% |
| 2022 Q4 | 72.03 Million SEK | 27.43% |
| 2022 Q3 | 56.52 Million SEK | 10.71% |
| 2022 Q2 | 51.05 Million SEK | 5.12% |
| 2021 FY | 154.3 Million SEK | 3.99% |
| 2021 Q2 | 38.26 Million SEK | 17.0% |
| 2021 Q3 | 41.02 Million SEK | 7.19% |
| 2021 Q4 | 41.55 Million SEK | 1.31% |
| 2021 Q1 | 32.7 Million SEK | -1.01% |
| 2020 Q2 | 39.59 Million SEK | -11.79% |
| 2020 Q3 | 30.87 Million SEK | -22.02% |
| 2020 FY | 148.38 Million SEK | -31.78% |
| 2020 Q4 | 33.04 Million SEK | 7.03% |
| 2020 Q1 | 44.88 Million SEK | -21.74% |
| 2019 Q2 | 50.62 Million SEK | 8.49% |
| 2019 FY | 217.52 Million SEK | 21.43% |
| 2019 Q4 | 57.35 Million SEK | -8.81% |
| 2019 Q3 | 62.88 Million SEK | 24.22% |
| 2019 Q1 | 46.66 Million SEK | -13.01% |
| 2018 Q3 | 40.63 Million SEK | 2.87% |
| 2018 Q4 | 53.64 Million SEK | 32.02% |
| 2018 Q1 | 44.76 Million SEK | 9.16% |
| 2018 FY | 179.14 Million SEK | 49.4% |
| 2018 Q2 | 39.5 Million SEK | -11.77% |
| 2017 Q3 | 26.39 Million SEK | -14.18% |
| 2017 FY | 119.9 Million SEK | 29.17% |
| 2017 Q1 | 21.73 Million SEK | -25.52% |
| 2017 Q2 | 30.75 Million SEK | 41.47% |
| 2017 Q4 | 41.01 Million SEK | 55.39% |
| 2016 Q2 | 29.63 Million SEK | 54.06% |
| 2016 Q1 | 19.23 Million SEK | -53.78% |
| 2016 FY | 92.82 Million SEK | 4.55% |
| 2016 Q4 | 29.18 Million SEK | 111.61% |
| 2016 Q3 | 13.79 Million SEK | -53.45% |
| 2015 FY | 88.78 Million SEK | 15.08% |
| 2015 Q3 | 14.96 Million SEK | 0.0% |
| 2015 Q4 | 41.62 Million SEK | 178.21% |
| 2014 FY | 77.15 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 79.72% |
| AcouSort AB (publ) | 25.87 Million SEK | -1086.775% |
| Active Biotech AB (publ) | 44.8 Million SEK | -585.331% |
| Alzinova AB (publ) | 36.39 Million SEK | -743.747% |
| Amniotics AB (publ) | 29.07 Million SEK | -956.308% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -1995.748% |
| BioArctic AB (publ) | 89.62 Million SEK | -242.631% |
| Camurus AB (publ) | 1.05 Billion SEK | 71.02% |
| Cantargia AB (publ) | 290.01 Million SEK | -5.887% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -1302.558% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -984.115% |
| Genovis AB (publ.) | 88.19 Million SEK | -248.186% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | -166.865% |
| Mendus AB (publ) | 129.13 Million SEK | -137.802% |
| Kancera AB (publ) | 63.07 Million SEK | -386.849% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -5464.233% |
| LIDDS AB (publ) | 27.75 Million SEK | -1006.551% |
| Lipum AB (publ) | 37.3 Million SEK | -723.143% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -4133.388% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | -125.948% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -1772.386% |
| NextCell Pharma AB | -576.01 Thousand SEK | 53412.478% |
| OncoZenge AB (publ) | 15.9 Million SEK | -1830.776% |
| Saniona AB (publ) | 1.07 Million SEK | -28413.463% |
| Simris Alg AB (publ) | 38.64 Million SEK | -694.705% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 4.484% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 14.13% |
| Xintela AB (publ) | 57.31 Million SEK | -435.784% |
| Ziccum AB (publ) | 27.87 Million SEK | -1001.55% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -4125.234% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | -68.978% |
| CombiGene AB (publ) | 44.14 Million SEK | -595.653% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | -114.768% |
| Intervacc AB (publ) | 79.78 Million SEK | -284.897% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -620.327% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -1636.64% |
| Corline Biomedical AB | 30.16 Million SEK | -917.933% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -429.183% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -269.236% |
| Aptahem AB (publ) | 10.01 Million SEK | -2966.93% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | -127.991% |
| Fluicell AB (publ) | 28.61 Million SEK | -973.103% |
| Biovica International AB (publ) | 133.72 Million SEK | -129.648% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -1451.743% |
| Abliva AB (publ) | 27.86 Million SEK | -1002.024% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | -58.703% |
| 2cureX AB (publ) | 36.51 Million SEK | -740.928% |
| I-Tech AB | 40.14 Million SEK | -664.895% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 64.269% |
| Cyxone AB (publ) | 28.21 Million SEK | -988.431% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -180.786% |
| Biosergen AB | 26.8 Million SEK | -1045.474% |
| Nanologica AB (publ) | 69.88 Million SEK | -339.409% |
| SynAct Pharma AB | 224.49 Million SEK | -36.791% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -595.151% |
| BioInvent International AB (publ) | 441.4 Million SEK | 30.429% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -1181.984% |
| Oncopeptides AB (publ) | 289.74 Million SEK | -5.986% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -3808.853% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | -176.872% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -1989.048% |